Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Alpha Cognition Inc C.ACOG

Alternate Symbol(s):  ACOGF

Healthcare Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

CSE:ACOG - Post Discussion

Alpha Cognition Inc > $ACOG.v Appoints New CFO
View:
Post by partystocker on Apr 12, 2022 12:46pm

$ACOG.v Appoints New CFO

As Alpha Cognition (TSXV: ACOG) enters its next phase of growth, the company has appointed Don Kalkofen as CFO. Don has considerable experience in corporate finance, as well as a strong track record of successfully supporting the financing of clinical-stage biotech company development.


https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/alpha-cognition-announces-change-of-cfo-grant-of-stock-options-and-addition-to-the-board-of-directors


With $ACOG.v working towards clinical trials for its ALPHA-0602 gene therapy, funding acquisition will be crucial going forward. I expect this appointment should lead to some promising updates from the company in the future. 


Shares of $ACOG.v have been bouncing around an 18% price range since February, and are currently trading at $.93. The company is currently valued at $57.19M.

 
Be the first to comment on this post
Alpha Cognition Inc